Ploegstra MJ, Ivy DD, Beghetti M, et al. Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry. Eur Heart J Qual Care Clin Outcomes. 2024;10(1):66–76.

Article  PubMed  Google Scholar 

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–731.

Article  CAS  PubMed  Google Scholar 

Janssen-Cilag International NV. Macitentan: EU prescribing information. 2024. https://www.ema.europa.eu/. Accessed 20 Dec 2024.

Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012;55(17):7849–61.

Article  CAS  PubMed  Google Scholar 

Keating GM. Macitentan: a review in pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2016;16(6):453–60.

Article  CAS  PubMed  Google Scholar 

Souza R, Delcroix M, Galie N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39:4374–90.

Article  PubMed  PubMed Central  Google Scholar 

McLaughlin VV, Channick R, Kim NH, et al. Safety of macitentan for the treatment of pulmonary hypertension: real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS). Pulm Circ. 2022. https://doi.org/10.1002/pul2.12150.

Article  PubMed  PubMed Central  Google Scholar 

Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.

Article  CAS  PubMed  Google Scholar 

European Commission. Union register of medical products for human use: Opsumit. 2024. https://ec.europa.eu/health/documents/community-register/html/h893.htm. Accessed 28 Jan 2025.

European Medicines Agency. Assessment report on a group of an extension of marketing authorisation and an extension of indication variation: Opsumit (Macitentan). EMA/389480/2024. 2024(Procedure No. EMEA/H/C/002697/X/0051/G):1-178.

Janssen-Cilag Ltd (a Johnson & Johnson Company). Macitentan 10 mg film-coated tablets: UK summary of product characteristics. 2024. https://products.mhra.gov.uk/. Accessed 10 Feb 2025.

Janssen-Cilag Ltd (a Johnson & Johnson Company). Macitentan 2.5 mg dispersible tablets: UK summary of product characteristics. 2024. https://products.mhra.gov.uk/. Accessed 12 Feb 2025.

Johnson & Johnson. Use of OPSUMIT in pediatrics with WHO Group I pulmonary hypertension. 2024. https://www.jnjmedicalconnect.com/. Accessed 20 Dec 2025.

Albinni S, Heno J, Pavo I, et al. Macitentan in the young: mid-term outcomes of patients with pulmonary hypertensive vascular disease treated in a pediatric tertiary care center. Paediatr Drugs. 2023;25(4):467–81.

Article  PubMed  PubMed Central  Google Scholar 

Schweintzger S, Koestenberger M, Schlagenhauf A, et al. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. Cardiovasc Diagn Ther. 2020;10(5):1675–85.

Article  PubMed  PubMed Central  Google Scholar 

Aypar E, Alehan D, Karagöz T, et al. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results. Cardiol Young. 2020;30(5):681–5.

Article  PubMed  Google Scholar 

Aypar E, Alehan D, Karagöz T, et al. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Cardiol Young. 2018;28(4):542–7.

Article  PubMed  Google Scholar 

Kashaki M, Mohazzab A, Radgoudarzi M, et al. Study on the comparison between bosentan and macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: a randomized double-blinded non-inferiority parallel clinical trial. Pediatr Neonatol. 2024;66(1):44–9.

Article  PubMed  Google Scholar 

Albinni S, Pavo I, Kitzmueller E, et al. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues—a single-centre experience. Pulm Circ. 2021;11(1):1–10.

Article  CAS  Google Scholar